drugset
drugset / Trial / NCT01543191

A Safety and Tolerability Study OF PUR118 In Subjects With Cystic Fibrosis

NCT01543191 ↗

Phase 1 Completed 10 enrolled Pulmatrix Inc. Celerion · collab
RandomizedCrossoverTriple-blindTreatment

Summary

The purpose of this study is to determine whether PUR118 is safe and tolerable in a population of subjects with Cystic Fibrosis.

Timeline

Start
2012-02
Primary completion
2012-12
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject PUR118 Unknown — —

Indications

cystic fibrosis